HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
ecabapide
Also Known As:
3-2-2-(3,4-dimethoxyphenyl)ethylamino-2-oxoethylamino-N-methylbenzamide; DQ 2511; DQ-2511; Benzamide, 3-((2-((2-(3,4-dimethoxyphenyl)ethyl)amino)-2-oxoethyl)amino)-N-methyl-
Networked:
10
relevant articles (
3
outcomes,
2
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Amides: 2428
Benzamides: 115
ecabapide: 10
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Benzene Derivatives: 17
Benzoates: 426
Benzamides: 115
ecabapide: 10
Carboxylic Acids: 973
Carbocyclic Acids
Benzoates: 426
Benzamides: 115
ecabapide: 10
Related Diseases
1.
Hemolytic Anemia
08/01/1996 - "
A possible mechanism of heinz body hemolytic anemia induced by DQ-2511, a new gastroprokinetic drug, in dogs.
"
02/01/1993 - "
Hemolytic anemia disappeared after a 4-week recovery period in the dogs that received DQ-2511.
"
02/01/1993 - "
Heinz body hemolytic anemia induced by DQ-2511, a new anti-ulcer drug, in dogs.
"
08/01/1996 - "
A previous study revealed that DQ-2511, a new gastroprokinetic drug, induced hemolytic anemia together with increased Heinz body formation, preceded by a marked decrease in erythrocyte reduced glutathione (GSH) content, after 2 weeks of dosing onward in dogs.
"
02/01/1993 - "
DQ-2511, a new anti-ulcer drug, was administered to beagle dogs for 4 weeks to investigate the mechanism whereby this drug induced hemolytic anemia and its reversibility in comparison with beta-acetylphenylhydrazine.
"
2.
Anemia
08/01/1996 - "
This difference in effects on GSH content may indicate the existence of a species difference in the anemia induced by DQ-2511.
"
08/01/1996 - "
Rats receiving DQ-2511 showed no anemia or any changes in erythrocyte GSH and Heinz body formation.
"
08/01/1996 - "
These results demonstrate that DQ-2511 causes a marked decrease in GSH in dogs, resulting in Heinz body anemia, whereas APHZ induces Heinz body formation after a significant increase in methemoglobin, and suggest that impairment of the GSH redox cycle and synthetases of GSH are not involved in the decreased GSH after DQ-2511 treatment.
"
02/01/1993 - "
These results suggest that decreases in reduced glutathione in erythrocytes play an important role in the anemia and Heinz body formation induced by DQ-2511, but not by beta-acetylphenylhydrazine.
"
3.
Stroke (Strokes)
12/01/1997 - "
Ecabapide, a novel gastroprokinetic agent, ameliorates gastric emptying of stroke-prone spontaneously hypertensive rats (SHRSP).
"
12/01/1997 - "
The effect of ecabapide, a novel gastroprokinetic agent, on gastric emptying was examined in stroke-prone spontaneously hypertensive rats (SHRSP), which are known to exhibit gastric malfunctions as a result of autonomic nervous system disorder.
"
4.
Vomiting
11/01/1995 - "
In dogs treated with cisplatin or copper sulfate, DQ-2511 had no antiemetic activity, as assessed by the number of vomiting episodes.
"
07/01/1998 - "
Thirteen-week oral repeated dose toxicity of ecabapide, a gastroprokinetic drug, was investigated in dogs at dosage levels of 50, 175 or 600 mg/kg, and in rats at dosage levels of 25, 100, 400 or 1600 mg/kg. In dogs, vomiting, aqueous salivation, body weight gain inhibition, and hemolytic anemia, together with an increase in Heinz body formation, were observed at 175 and/or 600 mg/kg. Histological examination revealed enhanced hemosiderin deposition in the liver and spleen, retention of erythrocytes in the splenic sinus and enhanced erythropoiesis in bone marrow at 175 and/or 600 mg/kg. In the rat study, although increases in serum total protein, albumin and calcium, as well as increased liver and kidney weights, were observed at 400 and/or 1600 mg/kg, no obvious morphological changes were seen.
"
5.
Body Weight (Weight, Body)
01/01/1995 - "
A 2-week treatment of SHR with DQ-2511 (1 mg/kg, oral) stimulated gastric emptying without affecting body weight gain or indirect systolic blood pressure (SBP), whereas cisapride (3 and 10 mg/kg, oral) had no effect under the same conditions.
"
07/01/1998 - "
Thirteen-week oral repeated dose toxicity of ecabapide, a gastroprokinetic drug, was investigated in dogs at dosage levels of 50, 175 or 600 mg/kg, and in rats at dosage levels of 25, 100, 400 or 1600 mg/kg. In dogs, vomiting, aqueous salivation, body weight gain inhibition, and hemolytic anemia, together with an increase in Heinz body formation, were observed at 175 and/or 600 mg/kg. Histological examination revealed enhanced hemosiderin deposition in the liver and spleen, retention of erythrocytes in the splenic sinus and enhanced erythropoiesis in bone marrow at 175 and/or 600 mg/kg. In the rat study, although increases in serum total protein, albumin and calcium, as well as increased liver and kidney weights, were observed at 400 and/or 1600 mg/kg, no obvious morphological changes were seen.
"
Related Drugs and Biologics
1.
Glutathione (Reduced Glutathione)
2.
Methemoglobin
3.
Ligases (Synthetase)
4.
Proteins (Proteins, Gene)
5.
Hemosiderin
6.
Calcium
7.
Albumins
8.
Cisapride (Propulsid)
9.
Acetic Acid (Vinegar)
10.
Copper Sulfate (Sulfate, Copper)